Evidence map›Paper›PMID 39605044›Full record

ArticleAIDS research and therapy2024

Ixekizumab: an alternative for HIV-positive psoriasis patients.

Fanghua Liu, Zhou Liu, Rongming Yang, Dandan Huang, Yongzhi Han

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fanghua Liu *Department of Dermatology, Ganzhou Municipal Hospital, Ganzhou, Jiangxi Province, 341000, People's Republic of China.
Zhou LiuDepartment of Dermatology, Ganzhou Municipal Hospital, Ganzhou, Jiangxi Province, 341000, People's Republic of China.
Rongming YangDepartment of Dermatology, Ganzhou Municipal Hospital, Ganzhou, Jiangxi Province, 341000, People's Republic of China.
Dandan HuangDepartment of Dermatology, Ganzhou Municipal Hospital, Ganzhou, Jiangxi Province, 341000, People's Republic of China.
Yongzhi Han *Department of Dermatology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106, Zhongshan Second Road, Guangzhou, Guangdong Province, 510080, People's Republic of China. hyzfriend@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).

Indexed as

Antibodies, Monoclonal, HumanizedHIV InfectionsPsoriasisAdultDermatologic AgentsHumansInterleukin-17MaleMiddle AgedTreatment OutcomeAntibodies, Monoclonal, HumanizedDermatologic AgentsInterleukin-17ixekizumabHIVIxekizumabPsoriasis

Identifiers

PMID39605044
PMCPMC11603802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.